{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T19:57:57Z","timestamp":1792699077702,"version":"4.5.0"},"reference-count":53,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2012,11,5]],"date-time":"2012-11-05T00:00:00Z","timestamp":1352073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Fibroblast growth factor 23 (FGF23) is a circulating factor secreted by osteocytes that is essential for phosphate homeostasis. In kidney proximal tubular cells FGF23 inhibits phosphate reabsorption and leads to decreased synthesis and enhanced catabolism of 1,25-dihydroxyvitamin D3 (1,25[OH]2D3). Excess levels of FGF23 cause renal phosphate wasting and suppression of circulating 1,25(OH)2D3 levels and are associated with several hereditary hypophosphatemic disorders with skeletal abnormalities, including X-linked hypophosphatemic rickets (XLH) and autosomal recessive hypophosphatemic rickets (ARHR). Currently, therapeutic approaches to these diseases are limited to treatment with activated vitamin D analogues and phosphate supplementation, often merely resulting in partial correction of the skeletal aberrations. In this study, we evaluate the use of FGFR inhibitors for the treatment of FGF23-mediated hypophosphatemic disorders using NVP-BGJ398, a novel selective, pan-specific FGFR inhibitor currently in Phase I clinical trials for cancer therapy. In two different hypophosphatemic mouse models, Hyp and Dmp1-null mice, resembling the human diseases XLH and ARHR, we find that pharmacological inhibition of FGFRs efficiently abrogates aberrant FGF23 signaling and normalizes the hypophosphatemic and hypocalcemic conditions of these mice. Correspondingly, long-term FGFR inhibition in Hyp mice leads to enhanced bone growth, increased mineralization, and reorganization of the disturbed growth plate structure. We therefore propose NVP-BGJ398 treatment as a novel approach for the therapy of FGF23-mediated hypophosphatemic diseases. \u00a9 2013 American Society for Bone and Mineral Research.<\/jats:p>","DOI":"10.1002\/jbmr.1810","type":"journal-article","created":{"date-parts":[[2012,11,5]],"date-time":"2012-11-05T18:56:16Z","timestamp":1352141776000},"page":"899-911","source":"Crossref","is-referenced-by-count":134,"title":["Pharmacological inhibition of fibroblast growth factor (FGF) receptor signaling ameliorates FGF23-mediated hypophosphatemic rickets"],"prefix":"10.1093","volume":"28","author":[{"given":"Simon","family":"W\u00f6hrle","sequence":"first","affiliation":[{"name":"Novartis Institutes for BioMedical Research, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Henninger","sequence":"additional","affiliation":[{"name":"Novartis Institutes for BioMedical Research, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Bonny","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology, University of Lausanne, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Thuery","sequence":"additional","affiliation":[{"name":"Novartis Institutes for BioMedical Research, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noemie","family":"Beluch","sequence":"additional","affiliation":[{"name":"Novartis Institutes for BioMedical Research, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy E","family":"Hynes","sequence":"additional","affiliation":[{"name":"Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vito","family":"Guagnano","sequence":"additional","affiliation":[{"name":"Novartis Institutes for BioMedical Research, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William R","family":"Sellers","sequence":"additional","affiliation":[{"name":"Novartis Institutes for BioMedical Research, Cambridge, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Hofmann","sequence":"additional","affiliation":[{"name":"Novartis Institutes for BioMedical Research, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"Kneissel","sequence":"additional","affiliation":[{"name":"Novartis Institutes for BioMedical Research, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Graus Porta","sequence":"additional","affiliation":[{"name":"Novartis Institutes for BioMedical Research, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2012,11,5]]},"reference":[{"key":"2024020318410544100_bib1","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/nrendo.2009.196","article-title":"The FGF23-Klotho axis: endocrine regulation of phosphate homeostasis","volume":"5","author":"Razzaque","year":"2009","journal-title":"Nat Rev Endocrinol."},{"key":"2024020318410544100_bib2","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1359\/JBMR.0301264","article-title":"FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis","volume":"19","author":"Shimada","year":"2004","journal-title":"J Bone Miner Res."},{"key":"2024020318410544100_bib3","doi-asserted-by":"crossref","first-page":"6500","DOI":"10.1073\/pnas.101545198","article-title":"Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia","volume":"98","author":"Shimada","year":"2001","journal-title":"Proc Natl Acad Sci U S A."},{"key":"2024020318410544100_bib4","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1111\/j.1523-1755.2005.00506.x","article-title":"Effect of fibroblast growth factor-23 on phosphate transport in proximal tubules","volume":"68","author":"Baum","year":"2005","journal-title":"Kidney Int."},{"key":"2024020318410544100_bib5","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.bbrc.2003.12.102","article-title":"FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa","volume":"314","author":"Shimada","year":"2004","journal-title":"Biochem Biophys Res Commun."},{"key":"2024020318410544100_bib6","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/nature05315","article-title":"Klotho converts canonical FGF receptor into a specific receptor for FGF23","volume":"444","author":"Urakawa","year":"2006","journal-title":"Nature."},{"key":"2024020318410544100_bib7","doi-asserted-by":"crossref","first-page":"6120","DOI":"10.1074\/jbc.C500457200","article-title":"Regulation of fibroblast growth factor-23 signaling by klotho","volume":"281","author":"Kurosu","year":"2006","journal-title":"J Biol Chem."},{"key":"2024020318410544100_bib8","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/36285","article-title":"Mutation of the mouse klotho gene leads to a syndrome resembling ageing","volume":"390","author":"Kuro-o","year":"1997","journal-title":"Nature."},{"key":"2024020318410544100_bib9","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1172\/JCI200419081","article-title":"Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism","volume":"113","author":"Shimada","year":"2004","journal-title":"J Clin Invest."},{"key":"2024020318410544100_bib10","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1210\/endo.143.2.8657","article-title":"Mediation of unusually high concentrations of 1,25-dihydroxyvitamin D in homozygous klotho mutant mice by increased expression of renal 1alpha-hydroxylase gene","volume":"143","author":"Yoshida","year":"2002","journal-title":"Endocrinology."},{"key":"2024020318410544100_bib11","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.matbio.2004.09.007","article-title":"Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice","volume":"23","author":"Sitara","year":"2004","journal-title":"Matrix Biol."},{"key":"2024020318410544100_bib12","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/81664","article-title":"The ADHR Consortium. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23","volume":"26","year":"2000","journal-title":"Nat Genet."},{"key":"2024020318410544100_bib13","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/ng1095-130","article-title":"The HYP Consortium. A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. The HYP Consortium","volume":"11","year":"1995","journal-title":"Nat Genet."},{"key":"2024020318410544100_bib14","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1038\/ng1868","article-title":"DMP1 mutations in autosomal recessive hypophosphatemia implicate a bone matrix protein in the regulation of phosphate homeostasis","volume":"38","author":"Lorenz-Depiereux","year":"2006","journal-title":"Nat Genet."},{"key":"2024020318410544100_bib15","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.ajhg.2010.01.010","article-title":"Autosomal-recessive hypophosphatemic rickets is associated with an inactivation mutation in the ENPP1 gene","volume":"86","author":"Levy-Litan","year":"2010","journal-title":"Am J Hum Genet."},{"key":"2024020318410544100_bib16","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.ajhg.2010.01.006","article-title":"Loss-of-function ENPP1 mutations cause both generalized arterial calcification of infancy and autosomal-recessive hypophosphatemic rickets","volume":"86","author":"Lorenz-Depiereux","year":"2010","journal-title":"Am J Hum Genet."},{"key":"2024020318410544100_bib17","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1046\/j.1523-1755.2001.00064.x","article-title":"Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23","volume":"60","author":"White","year":"2001","journal-title":"Kidney Int."},{"key":"2024020318410544100_bib18","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1038\/ng1905","article-title":"Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism","volume":"38","author":"Feng","year":"2006","journal-title":"Nat Genet."},{"key":"2024020318410544100_bib19","doi-asserted-by":"crossref","first-page":"E38","DOI":"10.1152\/ajpendo.00008.2006","article-title":"Pathogenic role of Fgf23 in Hyp mice","volume":"291","author":"Liu","year":"2006","journal-title":"Am J Physiol Endocrinol Metab."},{"key":"2024020318410544100_bib20","doi-asserted-by":"crossref","first-page":"E254","DOI":"10.1152\/ajpendo.90201.2008","article-title":"Pathogenic role of Fgf23 in Dmp1-null mice","volume":"295","author":"Liu","year":"2008","journal-title":"Am J Physiol Endocrinol Metab."},{"key":"2024020318410544100_bib21","doi-asserted-by":"crossref","first-page":"3702","DOI":"10.1096\/fj.08-123992","article-title":"Inactivation of klotho function induces hyperphosphatemia even in presence of high serum fibroblast growth factor 23 levels in a genetically engineered hypophosphatemic (Hyp) mouse model","volume":"23","author":"Nakatani","year":"2009","journal-title":"FASEB J."},{"issue":"3","key":"2024020318410544100_bib22","doi-asserted-by":"crossref","first-page":"E508","DOI":"10.1152\/ajpendo.00499.2010","article-title":"Compound deletion of FGFR3 and FGFR4 partially rescues the Hyp mouse phenotype","volume":"300","author":"Li","year":"2011","journal-title":"Am J Physiol Endocrinol Metab."},{"key":"2024020318410544100_bib23","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1681\/ASN.2007121301","article-title":"FGFR3 and FGFR4 do not mediate renal effects of FGF23","volume":"19","author":"Liu","year":"2008","journal-title":"J Am Soc Nephrol."},{"key":"2024020318410544100_bib24","doi-asserted-by":"crossref","first-page":"F282","DOI":"10.1152\/ajprenal.90742.2008","article-title":"FGF23 decreases renal NaPi-2a and NaPi-2c expression and induces hypophosphatemia in vivo predominantly via FGF receptor 1","volume":"297","author":"Gattineni","year":"2009","journal-title":"Am J Physiol Renal Physiol."},{"issue":"2","key":"2024020318410544100_bib25","doi-asserted-by":"crossref","first-page":"F371","DOI":"10.1152\/ajprenal.00740.2010","article-title":"Regulation of serum 1,25(OH)2 vitamin D3 levels by fibroblast growth factor 23 is mediated by FGF receptors 3 and 4","volume":"301","author":"Gattineni","year":"2011","journal-title":"Am J Physiol Renal Physiol."},{"key":"2024020318410544100_bib26","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1002\/jbmr.478","article-title":"FGF receptors control vitamin D and phosphate homeostasis by mediating renal FGF-23 signaling and regulating FGF-23 expression in bone","volume":"26","author":"Wohrle","year":"2011","journal-title":"J Bone Miner Res."},{"key":"2024020318410544100_bib27","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s00431-007-0662-1","article-title":"What's new in hypophosphataemic rickets?","volume":"167","author":"Pettifor","year":"2008","journal-title":"Eur J Pediatr."},{"key":"2024020318410544100_bib28","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1002\/jbmr.340","article-title":"A clinician's guide to X-linked hypophosphatemia","volume":"26","author":"Carpenter","year":"2011","journal-title":"J Bone Miner Res."},{"key":"2024020318410544100_bib29","doi-asserted-by":"crossref","first-page":"7066","DOI":"10.1021\/jm2006222","article-title":"Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phe nylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase","volume":"54","author":"Guagnano","year":"2011","journal-title":"J Med Chem."},{"key":"2024020318410544100_bib30","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1177\/154405910308201003","article-title":"The Dentin matrix protein 1 (Dmp1) is specifically expressed in mineralized, but not soft, tissues during development","volume":"82","author":"Feng","year":"2003","journal-title":"J Dent Res."},{"key":"2024020318410544100_bib31","doi-asserted-by":"crossref","first-page":"4667","DOI":"10.1073\/pnas.73.12.4667","article-title":"Hypophosphatemia: mouse model for human familial hypophosphatemic (vitamin D-resistant) rickets","volume":"73","author":"Eicher","year":"1976","journal-title":"Proc Natl Acad Sci U S A."},{"key":"2024020318410544100_bib32","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1002\/jbmr.5650020617","article-title":"Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee","volume":"2","author":"Parfitt","year":"1987","journal-title":"J Bone Miner Res."},{"key":"2024020318410544100_bib33","first-page":"LB122","article-title":"Abstract LB-122: A phase I dose escalation study of NVP-BGJ398, a selective pan FGFR inhibitor in genetically preselected advanced solid tumors","volume":"72","author":"Wolf","year":"2012","journal-title":"In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research. Philadelphia: AACR;"},{"key":"2024020318410544100_bib34","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1093\/hmg\/6.2.165","article-title":"Pex gene deletions in Gy and Hyp mice provide mouse models for X-linked hypophosphatemia","volume":"6","author":"Strom","year":"1997","journal-title":"Hum Mol Genet."},{"key":"2024020318410544100_bib35","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1002\/jbmr.401","article-title":"Fibroblast growth factor 23 regulates renal 1,25-dihydroxyvitamin D and phosphate metabolism via the MAP kinase signaling pathway in Hyp mice","volume":"26","author":"Ranch","year":"2011","journal-title":"J Bone Miner Res."},{"key":"2024020318410544100_bib36","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1359\/jbmr.090509","article-title":"Therapeutic effects of anti-FGF23 antibodies in hypophosphatemic rickets\/osteomalacia","volume":"24","author":"Aono","year":"2009","journal-title":"J Bone Miner Res."},{"issue":"8","key":"2024020318410544100_bib37","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1096\/fj.10-177816","article-title":"Bone proteins PHEX and DMP1 regulate fibroblastic growth factor Fgf23 expression in osteocytes through a common pathway involving FGF receptor (FGFR) signaling","volume":"25","author":"Martin","year":"2011","journal-title":"FASEB J."},{"key":"2024020318410544100_bib38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00774-011-0340-2","article-title":"The expanding family of hypophosphatemic syndromes","volume":"30","author":"Carpenter","year":"2012","journal-title":"J Bone Miner Metab."},{"key":"2024020318410544100_bib39","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1053\/j.ackd.2010.11.004","article-title":"Intestinal phosphate transport","volume":"18","author":"Sabbagh","year":"2011","journal-title":"Adv Chronic Kidney Dis."},{"key":"2024020318410544100_bib40","first-page":"4003","article-title":"The parathyroid is a target organ for FGF23 in rats","volume":"117","author":"Ben-Dov","year":"2007","journal-title":"J Clin Invest."},{"key":"2024020318410544100_bib41","doi-asserted-by":"crossref","first-page":"3937","DOI":"10.1073\/pnas.0700012104","article-title":"Skeletal overgrowth is mediated by deficiency in a specific isoform of fibroblast growth factor receptor 3","volume":"104","author":"Eswarakumar","year":"2007","journal-title":"Proc Natl Acad Sci U S A."},{"key":"2024020318410544100_bib42","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.bone.2010.06.018","article-title":"The role of pyrophosphate\/phosphate homeostasis in terminal differentiation and apoptosis of growth plate chondrocytes","volume":"47","author":"Kim","year":"2010","journal-title":"Bone."},{"key":"2024020318410544100_bib43","doi-asserted-by":"crossref","first-page":"9637","DOI":"10.1073\/pnas.0502249102","article-title":"Hypophosphatemia leads to rickets by impairing caspase-mediated apoptosis of hypertrophic chondrocytes","volume":"102","author":"Sabbagh","year":"2005","journal-title":"Proc Natl Acad Sci U S A."},{"key":"2024020318410544100_bib44","doi-asserted-by":"crossref","first-page":"4607","DOI":"10.1210\/en.2010-0354","article-title":"The receptor-dependent actions of 1,25-dihydroxyvitamin D are required for normal growth plate maturation in NPt2a knockout mice","volume":"151","author":"Miedlich","year":"2010","journal-title":"Endocrinology."},{"issue":"4","key":"2024020318410544100_bib45","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1210\/en.2011-1831","article-title":"Chronic inhibition of ERK1\/2 signaling improves disordered bone and mineral metabolism in hypophosphatemic (Hyp) mice","volume":"153","author":"Zhang","year":"2012","journal-title":"Endocrinology."},{"key":"2024020318410544100_bib46","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1210\/jc.2009-1671","article-title":"Treatment of X-linked hypophosphatemia with calcitriol and phosphate increases circulating fibroblast growth factor 23 concentrations","volume":"95","author":"Imel","year":"2010","journal-title":"J Clin Endocrinol Metab."},{"key":"2024020318410544100_bib47","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s00431-010-1382-5","article-title":"Fibroblast growth factor (FGF)23: a new hormone","volume":"170","author":"Alon","year":"2011","journal-title":"Eur J Pediatr."},{"key":"2024020318410544100_bib48","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.bbadis.2008.10.008","article-title":"Familial tumoral calcinosis and the role of O-glycosylation in the maintenance of phosphate homeostasis","volume":"1792","author":"Chefetz","year":"2009","journal-title":"Biochim Biophys Acta."},{"key":"2024020318410544100_bib49","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/hmg\/ddi034","article-title":"An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia","volume":"14","author":"Benet-Pages","year":"2005","journal-title":"Hum Mol Genet."},{"key":"2024020318410544100_bib50","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/jbmr.275","article-title":"Anti-FGF-23 neutralizing antibodies ameliorate muscle weakness and decreased spontaneous movement of Hyp mice","volume":"26","author":"Aono","year":"2011","journal-title":"J Bone Miner Res."},{"key":"2024020318410544100_bib51","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/978-1-4614-0887-1_3","article-title":"FGF23 and syndromes of abnormal renal phosphate handling","volume":"728","author":"Bergwitz","year":"2012","journal-title":"Adv Exp Med Biol."},{"key":"2024020318410544100_bib52","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1038\/sj.ki.5001788","article-title":"Post-transplant hypophosphatemia: tertiary \u2018hyper-phosphatoninism\u2019","volume":"70","author":"Bhan","year":"2006","journal-title":"Kidney Int."},{"key":"2024020318410544100_bib53","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1172\/JCI46122","article-title":"FGF23 induces left ventricular hypertrophy","volume":"121","author":"Faul","year":"2011","journal-title":"J Clin Invest."}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjbmr.1810","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/28\/4\/899\/56563213\/1810_ftp.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/28\/4\/899\/56563213\/1810_ftp.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T10:48:11Z","timestamp":1710326891000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/28\/4\/899-911\/7598643"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11,5]]},"references-count":53,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2012,11,5]]},"published-print":{"date-parts":[[2013,4,1]]}},"URL":"https:\/\/doi.org\/10.1002\/jbmr.1810","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.717993579.793474216","asserted-by":"object"}]},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2013,4,1]]},"published":{"date-parts":[[2012,11,5]]}}}